RESUMO
There is limited information about sodium valproate-induced hyperammonaemia encephalopathy (VPAIHE). The aim of this case report is to provide medical practitioners with a greater awareness of the possible development of hyperammonaemia due to sodium valproate use and its associated complications.This paper describes a middle-aged man with a history of bipolar affective disorder who was admitted with a manic relapse secondary to medication non-compliance. His admission was complicated by an intensive care unit admission to manage medical compromise in the context of sodium VPAIHE.
Assuntos
Transtorno Bipolar , Encefalopatias , Hiperamonemia , Masculino , Pessoa de Meia-Idade , Humanos , Ácido Valproico/efeitos adversos , Hiperamonemia/induzido quimicamente , Hiperamonemia/tratamento farmacológico , Recidiva Local de Neoplasia/tratamento farmacológico , Transtorno Bipolar/tratamento farmacológico , Transtorno Bipolar/psicologia , Encefalopatias/induzido quimicamente , Encefalopatias/tratamento farmacológicoRESUMO
OBJECTIVE: Long-acting injectable buprenorphine (LAI-BPN) was introduced in recent years as a novel treatment for opioid use disorder. Despite growing evidence-base of its effectiveness, there is limited research on the relationship between this treatment and patient characteristics. METHODS: This descriptive, retrospective cohort study compared sociodemographic and clinical variables between patients treated with SL-BPN and those treated with LAI-BPN at a large metropolitan health service in Queensland, Australia. RESULTS: Patients that transitioned to LAI-BPN were more likely to be single, have a comorbid mental illness, untreated hepatitis C infection and longer duration of unsanctioned opioid use. Patients continuing treatment with SL-BPN were more likely to fail to attend appointments and have urine drug screen results positive for gabapentinoids. CONCLUSIONS: The results of this study contribute to currently limited literature on this novel treatment option in an Australian context, highlighting factors which may influence patient and prescriber treatment choices. Clinicians may be more inclined to prescribe LAI-BPN to patients with higher psychosocial comorbidity to facilitate engagement in treatment.
Assuntos
Buprenorfina , Transtornos Relacionados ao Uso de Opioides , Humanos , Buprenorfina/uso terapêutico , Estudos Retrospectivos , Austrália , Transtornos Relacionados ao Uso de Opioides/tratamento farmacológico , Administração Sublingual , Analgésicos Opioides/uso terapêuticoRESUMO
There is limited information about promethazine-induced delirium with psychotic symptoms. The aim is to highlight the importance of taking a detailed history including medication use/abuse of both prescribed, illicit and over-the-counter preparations. This paper describes a patient who presented with delirium in the context of overuse of promethazine (Phenergan) which was initially missed. The patient was treated successfully, following the diagnosis of promethazine-induced delirium. Clinicians should be aware of assessing patients presenting with delirium to explore the possibility of over-the-counter medication misuse.
Assuntos
Delírio , Transtornos Relacionados ao Uso de Substâncias , Delírio/induzido quimicamente , Delírio/diagnóstico , Humanos , Medicamentos sem Prescrição/efeitos adversos , Prometazina/efeitos adversosRESUMO
There is minimal literature and case reports on cultural concepts of distress, especially on ghost sickness. The aim of this article is to educate clinicians to culture-bound syndromes/cultural concepts of distress when assessing people from culturally and linguistically diverse backgrounds. This case report describes an elderly male of Papua New Guinea who presented with psychotic symptoms, shaped by the cultural concept of distress from experiencing loss. This paper describes the importance of utilizing of cultural liaison officers to provide culturally-informed care and before diagnosing a patient with the culture concept of distress, every effort should be made to thoroughly investigate to exclude an organic cause for the presentation.
RESUMO
This paper describes a patient who presented with treatment-resistant depression with comorbid anxiety symptoms in the context of Huntington's disease (HD) and developed worsening movement disorder symptoms after commencing electroconvulsive therapy (ECT) for depression. The aim of this case report is to provide medical practitioners with a greater awareness of the possibility of worsening movement disorders when using ECT for depression in a patient with HD.
Assuntos
Transtorno Depressivo Maior/terapia , Progressão da Doença , Eletroconvulsoterapia/efeitos adversos , Doença de Huntington/psicologia , Ansiedade/complicações , Transtorno Depressivo Maior/complicações , Feminino , Humanos , Doença de Huntington/complicações , Pessoa de Meia-IdadeRESUMO
This paper describes a patient who presented with mania with psychotic features in the context of concomitant use of S-adenosyl-L-methionine (SAMe) and selective serotonin reuptake inhibitor (SSRI). The aim of this case report is to provide medical practitioners with a greater awareness of the possibility of a psychotic episode and/or mania manifesting with concurrent use of SAMe and SSRI.